Skip to content Skip to footer
Subscribe Now
Know Your Investor: Janus Henderson Group Plc (April’25 Edition)
INSIGHTS+

Know Your Investor: Janus Henderson Group Plc (April’25 Edition)

Shots:   Welcome to the 2025 series of Know Your Investor, featuring top venture capital firms focused on healthcare. This edition highlights Janus Henderson Group Plc, a global investment firm managing approximately $378.7B in assets across Equities, Fixed Income, Multi-Asset, and Alternatives. In 2024, the firm invested $5.36B across six funding rounds, adding 39 healthcare and…
April 3, 2025

Read more

VIEWPOINTS_Gregory Bell_2023
VIEWPOINTS

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Shots:Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s DiseaseHe also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…
May 30, 2023

Read more

Viewpoints_Jonathan Wall
VIEWPOINTS

Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Shots:Jonathan spoke about the data presented by Attralus at the XVIII International Symposium on Amyloidosis (ISA) as both oral and poster presentationsJonathan also talked about its lead candidate, AT-01. He discussed the study design of the P-I/II clinical trial evaluating AT-01The interview highlights Attralus vision to develop innovative medicines to improve the…
October 17, 2022

Read more